A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy

被引:24
|
作者
Lake, Jordan E. [1 ]
McComsey, Grace A. [2 ]
Hulgan, Todd M. [3 ]
Wanke, Christine A. [4 ]
Mangili, Alexandra [4 ]
Walmsley, Sharon L. [5 ]
Boger, M. Sean [6 ]
Turner, Ralph R. [7 ]
McCreath, Heather E. [1 ]
Currier, Judith S. [1 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[2] Case Western Reserve Univ, Dept Pediat & Med, Cleveland, OH 44106 USA
[3] Vanderbilt Univ, Dept Med, Nashville, TN USA
[4] Tufts Univ, Dept Med, Boston, MA 02111 USA
[5] Univ Toronto, Dept Med, Toronto, ON, Canada
[6] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[7] Phase V Technol Inc, Wellesley, MA USA
基金
美国国家卫生研究院;
关键词
REGIONAL ADIPOSE-TISSUE; ANTIRETROVIRAL THERAPY; INTRAABDOMINAL FAT; GENDER-DIFFERENCES; LIPOPROTEIN LEVELS; LIPODYSTROPHY; PREVALENCE; EFAVIRENZ; REGIMENS; LIPOATROPHY;
D O I
10.1089/apc.2012.0135
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Lipohypertrophy in HIV-infected patients is associated with metabolic abnormalities. Raltegravir (RAL) is not known to induce fat changes or severe metabolic perturbations. HIV-infected women with central adiposity and HIV-1 RNA less than 50 copies per milliliter on non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based antiretroviral therapy (ART) continued their nucleoside reverse transcriptase inhibitor (NRTI) backbone and were randomized to switch to open label RAL immediately or after 24 weeks. The primary end point was 24-week between-group change in computed tomography (CT)-quantified visceral adipose tissue (AT) volume. Fasting lipids, glucose, C-reactive protein (CRP), anthropometric measurements, and patient-reported quality of life assessments were also measured. Thirty-six subjects provided 80% power to detect a 10% between-group difference in visceral AT over 24 weeks. Thirty-seven of 39 enrolled subjects completed week 24. At entry, subjects were 75% black or Hispanic, and on 62% PI-based and 38% NNRTI-based regimens. The median age was 43 years, CD4 count 558 cells per microliter, and body mass index (BMI) 32 kg/m(2). After 24 weeks, no statistically significant changes in visceral or subcutaneous AT, anthropometrics, BMI, glucose, or CRP were observed. In subjects receiving RAL, significant improvements in total and LDL cholesterol (p = 0.04), self-reported belly size (p = 0.02) and composite body size (p = 0.02) were observed. Body size changes correlated well with percent visceral AT change. No RAL-related adverse events occurred. Compared to continued PI or NNRTI, switch to RAL was associated with statistically significant 24-week improvements in total and LDL cholesterol but not AT volumes. Additional insights into AT and metabolic changes in women on RAL will be provided by 48-week follow-up of the immediate-switch arm.
引用
收藏
页码:532 / 540
页数:9
相关论文
共 50 条
  • [1] Selective killing of HIV-infected cells by non-nucleoside reverse transcriptase inhibitor induced activation of HIV protease
    Jochmans, D.
    Anders, M.
    Keuleers, I.
    Smeulders, L.
    Kraeusslich, H. G.
    Kraus, G.
    Mueller, B.
    [J]. ANTIVIRAL THERAPY, 2010, 15 : A172 - A172
  • [2] Efficacy of Pravastatin in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and Protease Inhibitor (PI)-based HAART in HIV-Infected Patients
    Eaton, Susan A.
    Rahman, Anita P.
    Nguyen, Sean T.
    Bain, Amy M.
    Payne, Kenna D.
    Busti, Anthony J.
    [J]. AMERICAN JOURNAL OF INFECTIOUS DISEASES, 2008, 4 (02) : 124 - 130
  • [3] Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice
    Molto, Jose
    Blanco, Asuncion
    Miranda, Cristina
    Miranda, Jose
    Puig, Jordi
    Valle, Marta
    DelaVarga, Meritxell
    Fumaz, Carmina R.
    Barbanoj, Manuel Jose
    Clotet, Bonaventura
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (05) : 560 - 566
  • [4] Allergic reaction to non-nucleoside reverse transcriptase inhibitor in HIV-infected boy on HAART regimen
    Lackmann, GM
    Schmidt, B
    Niehues, T
    [J]. HAUTARZT, 2003, 54 (08): : 765 - 766
  • [5] MALARIA IN HIV-INFECTED CHILDREN RECEIVING HIV PROTEASE-INHIBITOR-COMPARED WITH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
    Hobbs, Charlotte V.
    Gabriel, Erin
    Kamthunzi, Portia
    Tegha, Gerald
    Petzold, Elizabeth Wills
    Barlow-Mosha, Linda
    Chi, Benjamin H.
    Li, Yonghua
    Ilmet, Tiina
    Kirmse, Brian
    Neal, Jillian
    Parikh, Sunil
    Deygoo, Nagamah
    Jean-Philippe, Patrick
    Mofenson, Lynne
    Prescott, William
    Musoke, Philippa
    Palumbo, Paul
    Duffy, Patrick E.
    Borkowsky, William
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 604 - 604
  • [6] Allergic reaction to non-nucleoside reverse-transcriptase inhibitor in an HIV-infected boy on HAART regimen
    Lackmann, GM
    Schmidt, B
    Niehues, T
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 2003, 151 (09) : 979 - 980
  • [7] HIV-1 non-nucleoside reverse transcriptase inhibitor
    Lloyd, AW
    [J]. DRUG DISCOVERY TODAY, 1998, 3 (08) : 387 - 387
  • [8] Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use?
    Pasquet, Armelle
    Viget, Nathalie
    Ajana, Faiza
    de la Tribonniere, Xavier
    Dubus, Sandrine
    Paccou, Julien
    Legroux-Gerot, Isabelle
    Melliez, Hugues
    Cortet, Bernard
    Yazdanpanah, Yazdan
    [J]. AIDS, 2011, 25 (06) : 873 - 874
  • [9] CHARACTERIZATION OF THE BIOTRANSFORMATION OF THE HIV NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR RILPIVIRINE
    Lade, Julie M.
    Bumpus, Namandje N.
    [J]. DRUG METABOLISM REVIEWS, 2014, 45 : 186 - 187
  • [10] Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection
    Ripamonti, Diego
    Maggiolo, Franco
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (08) : 899 - 912